المؤلفون: Hong, Yooha, Kang, Mi-Kyoung, Moon, Heui-Soo, Kim, Byung-Kun, Cho, Soo-Jin

المصدر: The Journal of Headache and Pain ; volume 24, issue 1 ; ISSN 1129-2377

مصطلحات موضوعية: Anesthesiology and Pain Medicine, Neurology (clinical), General Medicine

الوصف: Background Cluster headache is a severe and disabling primary headache disorder. Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide and a preventive therapy for episodic cluster headache. However, the approval and insurance coverage for episodic cluster headache differ in each country. Additionally, the consistency of efficacy of galcanezumab therapy has not yet been evaluated. This study aimed to assess the efficacy and safety of 240 mg of galcanezumab therapy for consecutive cluster bouts in patients with episodic cluster headache. Methods The study enrolled patients with episodic cluster headache who received two courses of galcanezumab therapy at three university hospitals in Republic of Korea between February 2020 and April 2022. The efficacy and safety of galcanezumab were analyzed by comparing daily headache frequency, the number of headache days, and headache intensity and adverse effects during the one-week period before and the third week after galcanezumab injection for each episode of cluster bouts. Paired t-test was used for comparing repeated data from different episodes of cluster bout. Results Sixteen patients were enrolled in this study. Fourteen patients received galcanezumab therapy for two consecutive cluster bouts. Galcanezumab was administered 24 days and 11 days after the first and second cluster bouts, respectively. The proportion of patients with 50% or more reduction in frequency of daily headache at week 3 from baseline was 86% and 64% during the first and second episodes, respectively. The proportion of patients who received transitional therapy before galcanezumab therapy was higher in the first episode of cluster bout than that in the second episode of cluster bout. No serious adverse reactions or significant differences in adverse effects between cluster bouts were noticed. Two patients received a second galcanezumab therapy during the pre-cluster period, and their cluster periods ended without typical cluster headache attacks 10–60 days after ...

الإتاحة: https://doi.org/10.1186/s10194-023-01661-7Test

المؤلفون: Lee, Mi Ji, Park, Jeong Wook, Chu, Min Kyung, Moon, Heui-Soo, Chung, Pil-Wook, Chung, Jae Myun, Sohn, Jong-Hee, Kim, Byung-Kun, Kim, Byung-Su, Kim, Soo-Kyoung, Song, Tae-Jin, Choi, Yun-Ju, Park, Kwang-Yeol, Oh, Kyungmi, Ahn, Jin-Young, Lee, Kwang-Soo, Bae, Dae Woong, Cho, Soo-Jin

المصدر: Cephalalgia ; volume 43, issue 4, page 033310242311596 ; ISSN 0333-1024 1468-2982

مصطلحات موضوعية: Neurology (clinical), General Medicine

الوصف: Background Only limited data are available regarding the treatment status and response to cluster headache in an Asian population. Therefore, this study aimed to provide a real-world treatment pattern of cluster headache and the response rate of each treatment in an Asian population. Methods Patients with cluster headache were recruited between September 2016 and January 2019 from 16 hospitals in Korea. At the baseline visit, we surveyed the patients about their previous experience of cluster headache treatment, and acute and/or preventive treatments were prescribed at the physician’s discretion. Treatment response was prospectively evaluated using a structured case-report form at 2 ± 2 weeks after baseline visit and reassessed after three months. Results Among 295 recruited patients, 262 experiencing active bouts were included. Only one-third of patients reported a previous experience of evidence-based treatment. At the baseline visit, oral triptans (73.4%), verapamil (68.3%), and systemic steroids (55.6%) were the three most common treatments prescribed by the investigators. Most treatments were given as combination. For acute treatment, oral triptans and oxygen were effective in 90.1% and 86.8% of the patients, respectively; for preventive treatment, evidence-based treatments, i.e. monotherapy or different combinations of verapamil, lithium, systemic steroids, and suboccipital steroid injection, helped 75.0% to 91.8% of patients. Conclusion Our data provide the first prospective analysis of treatment responses in an Asian population with cluster headache. The patients responded well to treatment despite the limited availability of treatment options, and this might be attributed at least in part by combination of medications. Most patients were previously undertreated, suggesting a need to raise awareness of cluster headache among primary physicians.

الإتاحة: https://doi.org/10.1177/03331024231159627Test

المؤلفون: Oh, Sun-Young, Kang, Jin-Ju, Park, Hong-Kyun, Cho, Soo-Jin, Hong, Yooha, Kang, Mi-Kyoung, Moon, Heui-Soo, Lee, Mi Ji, Song, Tae-Jin, Suh, Young Ju, Chu, Min Kyung

المصدر: Scientific Reports; 7/11/2024, Vol. 14 Issue 1, p1-11, 11p

مستخلص: Medication overuse headache (MOH) is a chronic headache disorder that results from excessive use of acutely symptomatic headache medications, leading to more frequent and severe headaches. This study aims to assess the 3-month treatment outcomes in MOH patients, focusing on the types and usage of overused medications, as well as preventive treatments. This prospective cross-sectional study analyzed the treatment outcomes of 309 MOH patients from April 2020 to March 2022. Patients were advised to discontinue overused medications immediately and offered preventive treatments based on clinical judgment. Data on headache characteristics, medication use, and impact on daily life were collected at baseline and 3 months. Results showed overall significant improvements in headache-related variables in patients completing the 3-month treatment follow-up. The median number of headache days per month decreased from 15 days at baseline to 8 days after 3 months (p < 0.001). Patients who overused multiple drug classes demonstrated increased disability levels (mean Headache Impact Test-6 score: 62 at baseline vs. 56 at 3 months, p < 0.01). Those who continued overusing medications reported more days of severe headache (mean 18 days at baseline vs. 14 days at 3 months, p < 0.05) and greater impact (mean Migraine Disability Assessment score: 35 at baseline vs. 28 after 3 months, p < 0.05) compared to the baseline. Differences in headache outcomes were evident across different preventive treatment groups, with generalized estimating equation analyses highlighting significant associations between clinical characteristics, overused medication classes, and preventive treatments. Most MOH clinical features significantly improved after 3 months of treatment. However, notable interactions were observed with certain clinical presentations, suggesting possible influences of overused medication classes, usage patterns, and preventive treatment types on MOH treatment outcomes. This study underscores the importance of individualized treatment strategies and the potential benefits of discontinuing overused medications. [ABSTRACT FROM AUTHOR]

: Copyright of Scientific Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Lee, Mi Ji, Park, Hong‐Kyun, Oh, Sun‐Young, Kang, Jin‐Ju, Hong, Yooha, Moon, Heui‐Soo, Song, Tae‐Jin, Chu, Min Kyung, Cho, Soo‐Jin

المساهمون: Korean Neurological Association

المصدر: Headache: The Journal of Head and Face Pain ; volume 64, issue 2, page 149-155 ; ISSN 0017-8748 1526-4610

الوصف: Objective To evaluate the efficacy of prednisolone in the treatment of medication‐overuse headache (MOH) using data from a multicenter prospective registry (Registry for Load and Management of Medication Overuse Headache [RELEASE]). Background The treatment of MOH is challenging, especially when withdrawal headache manifests during the cessation of overused medication. Although systemic corticosteroids have been empirically used to reduce withdrawal headaches, their efficacy on the long‐term outcomes of MOH has not been documented. Methods This was a post hoc analysis of the RELEASE study. The RELEASE is an ongoing multicenter observational cohort study in which patients with MOH have been recruited from seven hospitals in Korea since April 2020. Clinical characteristics, disease profiles, treatments, and outcomes were assessed at baseline and specific time points. We analyzed the effect of prednisolone on MOH reversal at 3 months. Results Among the 309 patients enrolled during the study period, prednisolone was prescribed to 59/309 (19.1%) patients at a dose ranging from 10 to 40 mg/day for 5–14 days; 228/309 patients (73.8%) completed the 3‐month follow‐up period. The MOH reversal rates at 3 months after baseline were 76% (31/41) in the prednisolone group and 57.8% (108/187) in the non‐prednisolone group ( p = 0.034). The effect of steroids remained significant (adjusted odds ratio 2.78, 95% confidence interval 1.27–6.1, p = 0.010) after adjusting for the number of monthly headache days at baseline, mode of discontinuation of overused medication, use of early preventive medications, and the number of preventive medications combined. Conclusions Although our observational study could not draw a definitive conclusion, prednisolone may be effective in the treatment of MOH.

الإتاحة: https://doi.org/10.1111/head.14667Test

المؤلفون: Mo, Heejung, Kim, Byung-Kun, Moon, Heui-Soo, Cho, Soo-Jin

المصدر: The Journal of Headache and Pain ; volume 23, issue 1 ; ISSN 1129-2369 1129-2377

مصطلحات موضوعية: Anesthesiology and Pain Medicine, Neurology (clinical), General Medicine

الوصف: Background Galcanezumab of 300 mg monthly is the FDA approved preventive medication for cluster headache (CH) during the cluster period. Compared to the 120 mg galcanezumab syringe for the treatment of migraines, the 100 mg syringe for CH has globally not been as widely available. The aim of our study was to investigate the preventive efficacy and tolerability of two 120 mg galcanezumab doses for episodic CH in clinical practices. Methods We evaluated patients with CH who received at least 1 dose of 240 mg (2 prefilled syringe of 120 mg) of galcanezumab in the 3 university hospitals from February 2020 to September 2021. In the patients with episodic CH, the efficacy and safety data of galcanezumab were analyzed regarding to the presence of the conventional preventive therapy at the timing of therapy of galcanezumab. The data of other subtypes of CH were separately described. Results In 47 patients with episodic CH, galcanezumab was started median 18 days after the onset of current bout (range 1–62 days) and 4 patients (10.8%) received second dose of galcanezumab. The median time to the first occurrence of 100% reduction from baseline in CH attacks per week after galcanezumab therapy was 17 days (25% to 75% quartile range: 5.0 ~ 29.5) in all patients with episodic CH, 15.5 days (3.8 ~ 22.1) in 36 patients with galcanezumab therapy add-on conventional preventive therapy, 21.0 days (12.0 ~ 31.5) in 11 patients started galcanezumab as initial preventive therapy. Among 33 patients with headache diary, the proportion of patients with 50% or more reduction in weekly CH attacks at week 3 from baseline were 78.8%. There was no significant difference in the proportion of patients with a reduction of at least 50% in weekly frequency of CH attacks at week 3 between 24 patients received galcanezumab therapy add-on conventional preventive therapy and 9 patient who received initial galcanezumab therapy. (83.3%, vs 66.7%, p = 0.36). There were no significant differences in proportion of “very much better or “much ...

الإتاحة: https://doi.org/10.1186/s10194-022-01505-wTest

المؤلفون: Kim, Byung-Su, Chung, Pil-Wook, Kim, Byung-Kun, Lee, Mi Ji, Chu, Min Kyung, Ahn, Jin-Young, Bae, Dae Woong, Song, Tae-Jin, Sohn, Jong-Hee, Oh, Kyungmi, Kim, Daeyoung, Kim, Jae-Moon, Park, Jeong Wook, Chung, Jae Myun, Moon, Heui-Soo, Cho, Soohyun, Seo, Jong-Geun, Kim, Soo-Kyoung, Choi, Yun-Ju, Park, Kwang-Yeol, Chung, Chin-Sang, Cho, Soo-Jin

المصدر: Frontiers in Neurology ; volume 13 ; ISSN 1664-2295

مصطلحات موضوعية: Neurology (clinical), Neurology

الوصف: Objective Cluster headache (CH) is a rare, primary headache disorder, characterized of excruciating, strictly one-sided pain attacks and ipsilateral cranial autonomic symptoms. Given the debilitating nature of CH, delayed diagnosis can increase the disease burden. Thus, we aimed to investigate the diagnostic delay, its predictors, and clinical influence among patients with CH. Methods Data from a prospective multicenter CH registry over a 4-year period were analyzed. CH was diagnosed according to the International Classification of Headache Disorders (ICHD)-3 criteria, and diagnostic delay of CH was assessed as the time interval between the year of the first onset and the year of CH diagnosis. Patients were classified into three groups according to the tertiles of diagnostic delay (1st tertile, <1 year; 2nd tertile, 1–6 years; and 3rd tertile, ≥7 years). Results Overall, 445 patients were evaluated. The mean duration of diagnosis delay was 5.7 ± 6.7 years, (range, 0–36 years). Regarding the age of onset, majority of young patients (age <20 years) belonged to the third tertile (60%), whereas minority of old patients (>40 years) belonged to the third tertile (9.0%). For year of onset, the proportion of patients in the 3rd tertile was the highest for the groups before the publication year of the ICHD-2 (74.7%) and the lowest for the groups after the publication year of the ICHD-3 beta version (0.5%). Compared with the first CH, episodic CH [multivariable-adjusted odds ratio (aOR) = 5.91, 95% CI = 2.42–14.48], chronic CH (aOR = 8.87, 95% CI = 2.66–29.51), and probable CH (aOR = 4.12, 95% CI = 1.48–11.43) were associated with the tertiles of diagnostic delay. Age of onset (aOR = 0.97, 95% CI = 0.95–0.99) and PHQ-9 score (aOR = 0.96, 95% CI = 0.93–0.99) were inversely associated with the tertile of diagnostic delay. The prevalence of suicidal ideation was highest in the patients of the third tertile. The mean HIT-6 score increased significantly with the diagnostic delay ( p = 0.041). Conclusions ...

الإتاحة: https://doi.org/10.3389/fneur.2022.827734Test

المؤلفون: Chu, Min Kyung, Kim, Byung-Su, Chung, Pil-Wook, Kim, Byung-Kun, Lee, Mi Ji, Park, Jeong Wook, Ahn, Jin-Young, Bae, Dae Woong, Song, Tae-Jin, Sohn, Jong-Hee, Oh, Kyungmi, Kim, Daeyoung, Kim, Jae-Moon, Kim, Soo-Kyoung, Choi, Yun-Ju, Chung, Jae Myun, Moon, Heui-Soo, Chung, Chin-Sang, Park, Kwang-Yeol, Cho, Soo-Jin

المساهمون: Yonsei University College of Medicine, National Research Foundation of Korea 2, Korean Neurological Association

المصدر: Scientific Reports ; volume 11, issue 1 ; ISSN 2045-2322

مصطلحات موضوعية: Multidisciplinary

الوصف: Although cranial autonomic symptoms (CAS) are typical in cluster headache (CH), some individuals with CH show no CAS during their headache attacks. Probable cluster headache (PCH) is a subtype of CH that fulfils all but one criterion of CH. This study aimed to investigate the frequency and clinical features of CH and PCH without CAS in comparison to those with CAS. We analysed data from the Korea Cluster Headache Registry, a prospective multicentre registry involving data from 16 hospitals. Of the 216 participants with CH and 26 with PCH, 19 (8.8%) and 7 (26.9%), respectively, did not have CAS. Participants with CH without CAS exhibited less severe anxiety (General Anxiety Disorder-7 score, median [interquartile range], 2.0 [1.0–6.0] vs 8.0 [3.0–12.0], p = 0.001) and depression (Patient Health Questionnaire-9 score, 3.0 [1.0–7.0] vs 7.0 [3.0–11.0], p = 0.042) than those with CAS. Among participants with PCH, headache intensity was less severe in participants without CAS than in those with CAS (numeric rating scale, 8.0 [7.0–8.0] vs 9.5 [8.0–10.0], p = 0.015). In conclusion, a significant proportion of participants with CH and PCH did not have CAS. Some clinical features of CH and PCH differed based on the presence of CAS.

الإتاحة: https://doi.org/10.1038/s41598-021-86408-7Test
https://www.nature.com/articles/s41598-021-86408-7.pdfTest
https://www.nature.com/articles/s41598-021-86408-7Test

المؤلفون: Sohn, Jong-Hee, Park, Jeong-Wook, Lee, Mi Ji, Chung, Pil-Wook, Chu, Min Kyung, Chung, Jae Myun, Ahn, Jin-Young, Kim, Byung-Su, Kim, Soo-Kyoung, Choi, Yun-Ju, Kim, Daeyoung, Song, Tae-Jin, Oh, Kyungmi, Moon, Heui-Soo, Park, Kwang-Yeol, Kim, Byung-Kun, Bae, Dae-Woong, Chung, Chin-Sang, Cho, Soo-Jin

المصدر: Scientific Reports ; volume 10, issue 1 ; ISSN 2045-2322

مصطلحات موضوعية: Multidisciplinary

الوصف: Although many patients with cluster headaches (CH) are disabled by their condition, few studies have examined this in detail. This cross-sectional, multicenter observational study prospectively collected demographic and clinical questionnaire data from 224 consecutive patients with CH. We assessed headache impact using the six-item Headache Impact Test (HIT-6) and evaluated the factors associated with the impact of CH. Participants with a HIT-6 score ≥ 60 were classified into a severe impact group. The majority (190, 84.8%) of the participants were classified into the severe impact group. These patients were characterized by younger age, earlier onset of CH, longer duration of each headache attack, higher pain intensity, more cranial autonomic symptoms, a higher proportion of depression or anxiety, higher score of stress, and lower score of quality of life. The anxiety (OR = 1.19, 95% CI: 1.08–1.31, p = 0.006), greater pain intensity (OR = 1.06, 95% CI: 1.02–1.10, p = 0.002), and age (OR = 0.99, 95% CI: 0.99–1.00, p = 0.008) were significant predictors for a severe impact of CH patients. According to the HIT-6 results, most of the CH patients were significantly affected by CH. As well as pain intensity, anxiety and age modulated CH’s impact on their lives.

الإتاحة: https://doi.org/10.1038/s41598-020-59366-9Test
https://www.nature.com/articles/s41598-020-59366-9.pdfTest
https://www.nature.com/articles/s41598-020-59366-9Test

المؤلفون: Kim, Byung-Su, Chung, Pil-Wook, Kim, Byung-Kun, Lee, Mi Ji, Park, Jeong Wook, Chu, Min Kyung, Ahn, Jin-Young, Bae, Dae Woong, Song, Tae-Jin, Sohn, Jong-Hee, Oh, Kyungmi, Kim, Daeyoung, Kim, Jae-Moon, Kim, Soo-Kyoung, Choi, Yun-Ju, Chung, Jae Myun, Moon, Heui-Soo, Chung, Chin-Sang, Park, Kwang-Yeol, Cho, Soo-Jin

المصدر: The Journal of Headache and Pain ; volume 21, issue 1 ; ISSN 1129-2369 1129-2377

مصطلحات موضوعية: Anesthesiology and Pain Medicine, Neurology (clinical), General Medicine

الوصف: Background Our aim was to investigate the relationship between coexisting cluster headache (CH) and migraine with anxiety and depression during active cluster bouts, and how symptoms change during remission. Methods We analyzed data from 222 consecutive CH patients and 99 age- and sex-matched controls using a prospective multicenter registry. Anxiety or depression was evaluated using the Generalized Anxiety Disorder-7 (GAD-7) or Patient Health Questionnaire-9 (PHQ-9), respectively. Moderate-to-severe anxiety or depression was defined as a score of ≥10 at baseline (during a cluster bout). We assessed for changes in anxiety and depression during CH remission periods. Results Among the CH patients, the prevalence of moderate-to-severe anxiety and depression was seen in 38.2% and 34.6%, respectively. Compared with controls, CH patients were associated with moderate-to-severe anxiety and depression (multivariable-adjusted odds ratio [aOR] = 7.32, 95% confidence intervals [CI] = 3.35–15.99 and aOR = 4.95, 95% CI = 2.32–10.57, respectively). CH patients with migraine were significantly more likely to have moderate-to-severe anxiety and depression (aOR = 32.53, 95% CI = 6.63–159.64 and aOR = 16.88, 95% CI = 4.16–68.38, respectively), compared to controls without migraine. The GAD-7 and PHQ-9 scores were significantly reduced between cluster bout and remission periods (from 6.8 ± 5.6 to 1.6 ± 2.8; P < 0.001, and from 6.1 ± 5.0 to 1.8 ± 2.4; P < 0.001, respectively). Conclusions Our results indicate that CH patients are at increased risk of anxiety and depression, especially in the presence of coexisting migraine. However, the anxiety and depression can improve during remission periods.

الإتاحة: https://doi.org/10.1186/s10194-020-01120-7Test

المؤلفون: Yu, Shengyuan, Kim, Byung-Kun, Guo, Aihong, Kim, Man-Ho, Zhang, Mingjie, Wang, Zhen, Liu, Jianguang, Moon, Heui-Soo, Tan, Ge, Yang, Qian, McGrath, Donnie, Hanna, Michael, Stock, David A, Gao, Yanfei, Croop, Robert, Lu, Zhihong

المصدر: The Lancet Neurology ; volume 22, issue 6, page 476-484 ; ISSN 1474-4422

مصطلحات موضوعية: Neurology (clinical)

الإتاحة: https://doi.org/10.1016/s1474-4422Test(23)00126-6
https://api.elsevier.com/content/article/PII:S1474442223001266?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1474442223001266?httpAccept=text/plainTest